Stephania longa

Stephania longa is a botanical extract derived from the plant *Stephania longa* Lour., a member of the Menispermaceae family used in Traditional Chinese Medicine (TCM). In the context of modern oncology, it is being investigated as a therapeutic component to enhance the efficacy of immune checkpoint inhibitors. Specifically, it is being evaluated in a Phase II clinical trial (ChiCTR2500114858) at Hainan General Hospital, where it is combined with Jiezai rice and the PD-1 inhibitor sintilimab. This combination therapy is intended for patients with advanced non-small cell lung cancer (NSCLC) who are PD-L1-positive and driver mutation-negative, and who have experienced treatment failure after first-line PD-(L)1-based immunotherapy. The therapeutic rationale likely involves the modulation of the tumor microenvironment or synergistic anti-tumor effects, although its precise molecular mechanisms in this combination remain under investigation.

Other names

Stephania longa Lour.Chang ye qian jin teng